COSMAX and Mass General Brigham Launch Skin Research

The organizations will collaborate through 2029 on microbiome data to develop new health and anti-aging products.

Updated on Oct. 21, 2026 in Beauty

Bold vector editorial illustration showing three glass petri dishes with colorful cultures, representing clinical research into skin microbiome and anti-aging technology. — COSMAX and Mass General Brigham have launched the VIVA Project in Boston to develop microbiome-based health and anti-aging ingredients through 2029. AI Illustration. Upload story photo >

Live Poll

Do you believe medical research partnerships between hospitals and companies improve the health products you use?

COSMAX has signed an agreement with Mass General Brigham in Boston to launch the VIVA Project, a multi-year research initiative. The partnership focuses on utilizing microbiome and clinical data to develop new functional ingredients.

Why it matters

This research aims to create high-value materials for metabolic management, weight control, and anti-aging solutions. By leveraging AI-based analysis, the project seeks to discover functional ingredients similar to GLP-1.

The VIVA Project is scheduled to span from 2026 to 2029 and follows the development of a Class 2 adhesive transparent wound dressing by COSMAX. Researchers will combine COSMAX skin microbiome data with MGB clinical information.

The players

COSMAX

This global health and beauty manufacturer specializes in research, development, and production for personal care and cosmetic brands.

Mass General Brigham

This is a non-profit hospital and physician network based in Massachusetts that serves as a major medical research hub.

The details

The collaboration builds on findings from an initial 2024 study that identified a mechanism for microorganism-derived substances to improve skin barriers and alleviate atopic dermatitis. These research findings have already led to a domestic patent application.

The first phase of basic and translational research began in 2024.
COSMAX signed the VIVA Project research agreement on October 21, 2026.
The VIVA Project research will run from 2026 to 2029.

Culture Shift

This collaboration reflects a broader trend in the beauty and health industry where clinical research and biotechnology are replacing traditional cosmetic formulas. The move positions the companies at the forefront of the shift toward scientifically validated, microbiome-focused wellness products.

Residents may see increased innovation originating from local medical institutions as this project progresses. The integration of clinical data into consumer product development could eventually lead to new, scientifically backed health and anti-aging options for shoppers.

The takeaway

The intersection of clinical research and consumer goods is accelerating as companies seek more precise, biology-based solutions for health and beauty. Consumers should look for future products that leverage this specific microbiome data for improved skin barrier health.